Alps Group Inc reported fiscal year 2026 financial results following its business combination with Globalink Investment Inc. in October 2025 and subsequent listing on the Nasdaq Global Market under ticker ALPS. Revenue grew 44% to $4.9 million from $3.4 million in the prior year, driven by growth in cellular therapy, medical testing, laboratory services, aesthetics beauty services, and healthcare products. The company reported a net loss of $2.1 million compared to $2.6 million previously, with gross profit increasing to $1.6 million and gross margin at approximately 32%. Administrative expenses rose to $3.5 million, largely due to $1.2 million in professional fees related to the business combination. The company also announced key leadership appointments, including Cheing Lye-Ping as CFO and Lee Hee Hang to the Board of Directors, alongside advancements in its NK Cell Therapy program and laboratory accreditation for Whole Genome Sequencing. Alps Group Inc is an integrated biotechnology platform headquartered in Malaysia operating across cell manufacturing, molecular diagnostics, and clinical delivery.